Target Blood Pressure and Kidney Disease
Authors: Yujiro Kida
Journal: Annals of Internal Medicine (2005)

Letters16 August 2005Target Blood Pressure and Kidney DiseaseYujiro Kida, MD, PhDYujiro Kida, MD, PhDFrom Tsurumi University School of Dental Medicine and Tokyo Medical and Dental University, Yokohama 230-8501, Japan.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-4-200508160-00018 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Sarnak and colleagues (1) concluded that a low target blood pressure slowed the progression of nondiabetic kidney disease. However, Ruggenenti and associates (2) recently reported that no additional benefit from further blood pressure reduction by felodipine (dihydropyridine calcium-channel blockers) could be shown in patients with nondiabetic proteinuric nephropathies receiving background angiotensin-converting enzyme (ACE) inhibitor therapy. As Sarnak and colleagues pointed out, more participants in the low target blood pressure group received ACE inhibitors in their study (1). Angiotensin-converting enzyme inhibitors are known to slow progression of kidney disease independently of their blood pressure–lowering effect (3). In the ...References1. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342-51. [PMID: 15738453] LinkGoogle Scholar2. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939-46. [PMID: 15766995] CrossrefMedlineGoogle Scholar3. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135:73-87. [PMID: 11453706] LinkGoogle Scholar4. Wright JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-31. [PMID: 12435255] CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Yujiro Kida, MD, PhDAffiliations: From Tsurumi University School of Dental Medicine and Tokyo Medical and Dental University, Yokohama 230-8501, Japan.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoAngiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease Tazeen H. Jafar , Christopher H. Schmid , Marcia Landa , Ioannis Giatras , Robert Toto , Giuseppe Remuzzi , Giuseppe Maschio , Barry M. Brenner , Annelise Kamper , Pietro Zucchelli , Gavin Becker , Andres Himmelmann , Kym Bannister , Paul Landais , Shahnaz Shahinfar , Paul E. de Jong , Dick de Zeeuw , Joseph Lau , Andrew S. Levey , and The Effect of a Lower Target Blood Pressure on the Progression of Kidney Disease: Long-Term Follow-up of the Modification of Diet in Renal Disease Study Mark J. Sarnak , Tom Greene , Xuelei Wang , Gerald Beck , John W. Kusek , Allan J. Collins , and Andrew S. Levey Target Blood Pressure and Kidney Disease Mark J. Sarnak , Andrew S. Levey , and Tom Greene Target Blood Pressure and Kidney Disease Chester B. Good Metrics 16 August 2005Volume 143, Issue 4Page: 310-311KeywordsACE inhibitorsAngiotensin converting enzyme inhibitorAntihypertensive drug therapyBloodBlood groupsBlood pressureConflicts of interestHypertensionProteinsRenal diseases ePublished: 16 August 2005 Issue Published: 16 August 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...